{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:26:35Z","timestamp":1794360395674,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P35542-B"],"award-info":[{"award-number":["P35542-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u00d6sterreichische Muskelforschung","award":["AP00957OFF"],"award-info":[{"award-number":["AP00957OFF"]}]},{"name":"Ludwig Boltzmann Cardiovascular Institute","award":["LBI-CARREM 2019-24"],"award-info":[{"award-number":["LBI-CARREM 2019-24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Duchenne muscular dystrophy (DMD), a severe muscle disease caused by mutations in the gene encoding for the intracellular protein dystrophin, is associated with impaired cardiac function and arrhythmias. A causative factor for complications in the dystrophic heart is abnormal calcium (Ca) handling in ventricular cardiomyocytes, and restoration of normal Ca homeostasis has emerged as therapeutic strategy. Here, we used a rodent model of DMD, the dystrophin-deficient DMD<jats:sup>mdx<\/jats:sup> rat, to test the following hypothesis: chronic administration of ivabradine (IVA), a drug clinically approved for the treatment of heart failure, improves Ca handling in dystrophic ventricular cardiomyocytes and thereby enhances contractile performance in the dystrophic heart. Intracellular Ca measurements revealed that 4-months administration of IVA to DMD<jats:sup>mdx<\/jats:sup> rats significantly improves Ca handling properties in dystrophic ventricular cardiomyocytes. In particular, IVA treatment increased electrically-evoked Ca transients and speeded their decay. This suggested enhanced sarcoplasmic reticulum Ca release and faster removal of Ca from the cytosol. Chronic IVA administration also enhanced the sarcoplasmic reticulum Ca load. Transthoracic echocardiography revealed a significant improvement of cardiac systolic function in IVA-treated DMD<jats:sup>mdx<\/jats:sup> rats. Thus, left ventricular ejection fraction and fractional shortening were enhanced, and end-systolic as well as end-diastolic diameters were diminished by the drug. Finally, chronic IVA administration neither significantly attenuated cardiac fibrosis and apoptosis, nor was vascular function improved by the drug. Collectively our findings suggest that long-term IVA administration enhances contractile function in the dystrophic heart by improvement of Ca handling in ventricular cardiomyocytes. Chronic IVA administration may be beneficial for DMD patients.<\/jats:p>","DOI":"10.1038\/s41598-025-92927-4","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T13:37:38Z","timestamp":1742045858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronic administration of ivabradine improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"15","author":[{"given":"Jessica","family":"Marksteiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dostal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Lujza","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno K.","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simge","family":"Baydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I. A.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kratochwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Fichtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Kubista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lilliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Todt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xaver","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Hilber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"92927_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2042098610393209","volume":"2","author":"GF Rushworth","year":"2011","unstructured":"Rushworth, G. F., Lambrakis, P. & Leslie, S. J. Ivabradine: A new rate-limiting therapy for coronary artery disease and heart failure. Ther. Adv. drug Saf. 2, 19\u201328 (2011).","journal-title":"Ther. Adv. drug Saf."},{"key":"92927_CR2","first-page":"689","volume":"8","author":"P Scicchitano","year":"2014","unstructured":"Scicchitano, P. et al. Ivabradine, coronary artery disease, and heart failure: Beyond rhythm control. Drug Des. Devel. Ther. 8, 689\u2013700 (2014).","journal-title":"Drug Des. Devel. Ther."},{"key":"92927_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth, J. S., Lala, A., Pinney, S., Reddy, V. Y. & Dukkipati, S. R. The clinical use of ivabradine. J. Am. Coll. Cardiol. 70, 1777\u20131784 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"92927_CR4","doi-asserted-by":"publisher","first-page":"1149351","DOI":"10.3389\/fcvm.2023.1149351","volume":"10","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: A systematic review and meta-analysis. Front. Cardiovasc. Med. 10, 1149351 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"92927_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s00059-012-3643-8","volume":"37","author":"J Finsterer","year":"2012","unstructured":"Finsterer, J., St\u00f6llberger, C. & Berger, E. Beneficial effect of ivabradine in dilated cardiomyopathy from Becker muscular dystrophy. Herz 37, 702\u2013705 (2012).","journal-title":"Herz"},{"key":"92927_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ijcard.2016.08.135","volume":"223","author":"G De Benedittis","year":"2016","unstructured":"De Benedittis, G. et al. Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: A chance for slowing progression of heart failure?. Int. J. Cardiol. 223, 286\u2013288 (2016).","journal-title":"Int. J. Cardiol."},{"key":"92927_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2019.01.052","volume":"280","author":"R Adorisio","year":"2019","unstructured":"Adorisio, R. et al. Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. Int. J. Cardiol. 280, 99\u2013103 (2019).","journal-title":"Int. J. Cardiol."},{"key":"92927_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1536\/ihj.23-563","volume":"65","author":"A Wakisaka","year":"2024","unstructured":"Wakisaka, A. et al. Efficacy and tolerability of ivabradine for cardiomyopathy in patients with duchenne muscular dystrophy. Int. Heart J. 65, 211\u2013217 (2024).","journal-title":"Int. Heart J."},{"key":"92927_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1538\/expanim.23-0087","volume":"73","author":"R Tochinai","year":"2024","unstructured":"Tochinai, R. et al. Ivabradine ameliorates cardiomyopathy progression in a Duchenne muscular dystrophy model rat. Exp. Anim. 73, 145\u2013153 (2024).","journal-title":"Exp. Anim."},{"key":"92927_CR10","doi-asserted-by":"publisher","first-page":"dmm047704","DOI":"10.1242\/dmm.047704","volume":"14","author":"PL Szab\u00f3","year":"2021","unstructured":"Szab\u00f3, P. L. et al. Cardiovascular phenotype of the Dmd mdx rat\u2014A suitable animal model for Duchenne muscular dystrophy. Dis. Model. Mech. 14, dmm047704 (2021).","journal-title":"Dis. Model. Mech."},{"key":"92927_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.scr.2013.12.004","volume":"12","author":"X Guan","year":"2014","unstructured":"Guan, X. et al. Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery. Stem Cell Res. 12, 467\u2013480 (2014).","journal-title":"Stem Cell Res."},{"key":"92927_CR12","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","volume":"67","author":"F Kamdar","year":"2016","unstructured":"Kamdar, F. & Garry, D. J. Dystrophin-deficient cardiomyopathy. J. Am. Coll. Cardiol. 67, 2533\u20132546 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"92927_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/jcm9020520","volume":"9","author":"ML Law","year":"2020","unstructured":"Law, M. L., Cohen, H., Martin, A. A., Angulski, A. B. B. & Metzger, J. M. Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: Mechanisms and experimental therapeutic strategies. J. Clin. Med. 9, 520 (2020).","journal-title":"J. Clin. Med."},{"key":"92927_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bbrc.2019.09.095","volume":"520","author":"M Sato","year":"2019","unstructured":"Sato, M. et al. Amelioration of intracellular Ca2+ regulation by exon-45 skipping in Duchenne muscular dystrophy-induced pluripotent stem cell-derived cardiomyocytes. Biochem. Biophys. Res. Commun. 520, 179\u2013185 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"92927_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110371","volume":"9","author":"T Larcher","year":"2014","unstructured":"Larcher, T. et al. Characterization of dystrophin deficient rats: A new model for Duchenne muscular dystrophy. PLoS One 9, e110371 (2014).","journal-title":"PLoS One"},{"key":"92927_CR16","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15664","volume":"11","author":"PL Szabo","year":"2023","unstructured":"Szabo, P. L. et al. Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy. Physiol. Rep. 11, e15664 (2023).","journal-title":"Physiol. Rep."},{"key":"92927_CR17","doi-asserted-by":"publisher","first-page":"H846","DOI":"10.1152\/ajpheart.00688.2006","volume":"292","author":"IA Williams","year":"2007","unstructured":"Williams, I. A. & Allen, D. G. Intracellular calcium handling in ventricular myocytes from mdx mice. Am. J. Physiol. Heart Circ. Physiol. 292, H846\u2013H855 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"92927_CR18","first-page":"H1091","volume":"270","author":"AM Gunteski-Hamblin","year":"1996","unstructured":"Gunteski-Hamblin, A. M. et al. Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. Am. J. Physiol. 270, H1091\u2013H1100 (1996).","journal-title":"Am. J. Physiol."},{"key":"92927_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.bbrc.2004.07.127","volume":"322","author":"MA Kaetzel","year":"2004","unstructured":"Kaetzel, M. A. & Dedman, J. R. Annexin VI regulation of cardiac function. Biochem. Biophys. Res. Commun. 322, 1171\u20131177 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"92927_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1096\/fj.01-0892fje","volume":"16","author":"G Song","year":"2002","unstructured":"Song, G. et al. Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin 6 null-mutant mice. FASEB J. 16, 622\u2013624 (2002).","journal-title":"FASEB J."},{"key":"92927_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cardiores.2004.11.010","volume":"65","author":"E Camors","year":"2005","unstructured":"Camors, E., Monceau, V. & Charlemagne, D. Annexins and Ca2+ handling in the heart. Cardiovasc. Res. 65, 793\u2013802 (2005).","journal-title":"Cardiovasc. Res."},{"key":"92927_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamacardio.2016.4801","volume":"2","author":"MC Silva","year":"2017","unstructured":"Silva, M. C. et al. Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: A randomized clinical trial. JAMA Cardiol. 2, 190\u2013199 (2017).","journal-title":"JAMA Cardiol."},{"key":"92927_CR23","doi-asserted-by":"crossref","unstructured":"On\u00f3di, Z. et al. Inflammasome activity in the skeletal muscle and heart of rodent models for Duchenne muscular dystrophy. Int. J. Mol. Sci. 24, (2023).","DOI":"10.3390\/ijms24108497"},{"issue":"Pt 6","key":"92927_CR24","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1242\/jcs.108.6.2197","volume":"108","author":"JG Tidball","year":"1995","unstructured":"Tidball, J. G., Albrecht, D. E., Lokensgard, B. E. & Spencer, M. J. Apoptosis precedes necrosis of dystrophin-deficient muscle. J. Cell Sci. 108(Pt 6), 2197\u20132204 (1995).","journal-title":"J. Cell Sci."},{"key":"92927_CR25","doi-asserted-by":"publisher","first-page":"D1","DOI":"10.2741\/A589","volume":"6","author":"V Adams","year":"2001","unstructured":"Adams, V., Gielen, S., Hambrecht, R. & Schuler, G. Apoptosis in skeletal muscle. Front. Biosci. 6, D1\u2013D11 (2001).","journal-title":"Front. Biosci."},{"key":"92927_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/HJH.0000000000001984","volume":"37","author":"AL Hohneck","year":"2019","unstructured":"Hohneck, A. L. et al. Effects of heart rate reductionwith ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. J. Hypertens. 37, 1023\u20131031 (2019).","journal-title":"J. Hypertens."},{"key":"92927_CR27","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.107.746537","volume":"117","author":"F Custodis","year":"2008","unstructured":"Custodis, F. et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117, 2377\u20132387 (2008).","journal-title":"Circulation"},{"key":"92927_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/cvr\/cvs318","volume":"97","author":"M Navaratnarajah","year":"2013","unstructured":"Navaratnarajah, M. et al. Influence of ivabradine on reverse remodelling during mechanical unloading. Cardiovasc. Res. 97, 230\u2013239 (2013).","journal-title":"Cardiovasc. Res."},{"key":"92927_CR29","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/eurheartj\/ehp554","volume":"31","author":"N Couvreur","year":"2010","unstructured":"Couvreur, N. et al. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12\/12.6 expression. Eur. Heart J. 31, 1529\u20131537 (2010).","journal-title":"Eur. Heart J."},{"key":"92927_CR30","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1093\/eurheartj\/ehs218","volume":"34","author":"JC Reil","year":"2013","unstructured":"Reil, J. C. et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur. Heart J. 34, 2839\u20132849 (2013).","journal-title":"Eur. Heart J."},{"key":"92927_CR31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1073\/pnas.0908540107","volume":"107","author":"J Fauconnier","year":"2010","unstructured":"Fauconnier, J. et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA. 107, 1559\u20131564 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"92927_CR32","doi-asserted-by":"publisher","first-page":"H710","DOI":"10.1152\/ajpheart.00890.2013","volume":"307","author":"DR Gonzalez","year":"2014","unstructured":"Gonzalez, D. R. et al. NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 307, H710\u2013H721 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"92927_CR33","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41467-017-01146-7","volume":"8","author":"A Voit","year":"2017","unstructured":"Voit, A. et al. Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice. Nat. Commun. 8, 1068 (2017).","journal-title":"Nat. Commun."},{"key":"92927_CR34","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13567","volume":"6","author":"L Rubi","year":"2018","unstructured":"Rubi, L., Todt, H., Kubista, H., Koenig, X. & Hilber, K. Calcium current properties in dystrophin-deficient ventricular cardiomyocytes from aged mdx mice. Physiol. Rep. 6, e13567 (2018).","journal-title":"Physiol. Rep."},{"key":"92927_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1025473606484","volume":"24","author":"JP Benitah","year":"2003","unstructured":"Benitah, J. P., Gomez, A. M., Virsolvy, A. & Richard, S. New perspectives on the key role of calcium in the progression of heart disease. J. Muscle Res. Cell Motil. 24, 275\u2013283 (2003).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"92927_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/01.CIR.85.3.1046","volume":"85","author":"DJ Beuckelmann","year":"1992","unstructured":"Beuckelmann, D. J., N\u00e4bauer, M. & Erdmann, E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85, 1046\u20131055 (1992).","journal-title":"Circulation"},{"key":"92927_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/5584_2017_106","volume":"1067","author":"J Gambardella","year":"2018","unstructured":"Gambardella, J., Trimarco, B., Iaccarino, G. & Santulli, G. New insights in cardiac calcium handling and excitation-contraction coupling. Adv. Exp. Med. Biol. 1067, 373\u2013385 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"92927_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1161\/01.CIR.92.5.1169","volume":"92","author":"B Pieske","year":"1995","unstructured":"Pieske, B. et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92, 1169\u20131178 (1995).","journal-title":"Circulation"},{"key":"92927_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijcard.2017.02.046","volume":"236","author":"G Niccoli","year":"2017","unstructured":"Niccoli, G., Borovac, J. A., Vetrugno, V., Camici, P. G. & Crea, F. Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering. Int. J. Cardiol. 236, 107\u2013112 (2017).","journal-title":"Int. J. Cardiol."},{"key":"92927_CR40","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1111\/bph.13220","volume":"172","author":"P Kleinbongard","year":"2015","unstructured":"Kleinbongard, P. et al. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br. J. Pharmacol. 172, 4380\u20134390 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"92927_CR41","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1111\/jcmm.16341","volume":"25","author":"LN Mekies","year":"2021","unstructured":"Mekies, L. N. et al. Depressed \u03b2-adrenergic inotropic responsiveness and intracellular calcium handling abnormalities in Duchenne Muscular Dystrophy patients\u2019 induced pluripotent stem cell-derived cardiomyocytes. J. Cell. Mol. Med. 25, 3922\u20133934 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"92927_CR42","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1476-5381.2011.01627.x","volume":"165","author":"S Suffredini","year":"2012","unstructured":"Suffredini, S. et al. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. Br. J. Pharmacol. 165, 1457\u20131466 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"92927_CR43","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","volume":"109","author":"P Mulder","year":"2004","unstructured":"Mulder, P. et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109, 1674\u20131679 (2004).","journal-title":"Circulation"},{"key":"92927_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020300","volume":"6","author":"X Koenig","year":"2011","unstructured":"Koenig, X. et al. Voltage-gated ion channel dysfunction precedes cardiomyopathy development in the dystrophic heart. PLoS One 6, e20300 (2011).","journal-title":"PLoS One"},{"key":"92927_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2019.03.003","volume":"285","author":"PM Pilz","year":"2019","unstructured":"Pilz, P. M. et al. Remote ischemic perconditioning attenuates adverse cardiac remodeling and preserves left ventricular function in a rat model of reperfused myocardial infarction. Int. J. Cardiol. 285, 72\u201379 (2019).","journal-title":"Int. J. Cardiol."},{"key":"92927_CR46","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/cvr\/cvx151","volume":"113","author":"MB Sikkel","year":"2017","unstructured":"Sikkel, M. B. et al. Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. Cardiovasc. Res. 113, 1743\u20131752 (2017).","journal-title":"Cardiovasc. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92927-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T01:24:18Z","timestamp":1742088258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92927-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92927"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92927-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is reported in accordance with ARRIVE guidelines. No conflicts of interest, financial or otherwise, are declared by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8991"}}